Tech Company Financing Transactions
Tranzyme Pharma Funding Round
Tranzyme Pharma secured a $32 million funding round on 5/13/2005. Backers included H.I.G. Capital and Quaker Partners.
Transaction Overview
Company Name
Announced On
5/13/2005
Transaction Type
Venture Equity
Amount
$32,000,000
Round
Undisclosed
Investors
H.I.G. Capital (Lead Investor) (Aaron Davidson)
Quaker Partners (Brenda Gavin)
Proceeds Purpose
The financing will allow the company to accelerate the clinical development of their lead compounds and focus on additional discovery and pre-clinical development efforts to expand their pipeline.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
5001 South Miami Blvd. 300
Durham, NC 27703
USA
Durham, NC 27703
USA
Phone
Website
Email Address
Overview
Tranzyme Pharma (NASDAQ: TZYM) is a leading biopharmaceutical company developing novel orally bioavailable, small molecule therapeutics for the treatment of gastrointestinal (GI) diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Linda Grais
Chief Financial Officer
Michael Byrnes
Browse more venture capital transactions:
Prev: 5/13/2005: OraMetrix venture capital transaction
Next: 5/13/2005: Five9 venture capital transaction
Share this article
News on VC Transactions
We do our best to document every notable VC transaction. All VC database entries on this site come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs